Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colpofix is a vaginal gel formulation containing carboxymethyl beta-glucan and polycarbophil, developed for the prevention and treatment of cervical lesions caused by human papillomavirus (HPV). It is classified as a topical medical device that functions through a mucoadhesive mechanism; the polycarbophil component forms a protective film on the cervical mucosa, ensuring prolonged contact for the active ingredients. Carboxymethyl beta-glucan, a chemically modified polysaccharide, acts by modulating the local immune response to facilitate the clearance of HPV infection and the regression of low-grade cervical intraepithelial lesions (CIN1). The product originated in Italy and is marketed by Uriach Consumer Healthcare, with clinical evidence supported by studies involving over 2,000 patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carboxymethyl-beta-glucan + polycarbophil.